Current and future therapeutic approaches for osteosarcoma
- 14 December 2017
- journal article
- review article
- Published by Taylor & Francis Ltd in Expert Review of Anticancer Therapy
- Vol. 18 (1), 39-50
- https://doi.org/10.1080/14737140.2018.1413939
Abstract
Introduction: Current treatment of osteosarcoma includes surgical resection of all gross disease in conjunction with systemic chemotherapy to control micro-metastatic disease. This yields a 5-year event free survival (EFS) of approximately 70% for patients with localized osteosarcoma while patients with metastatic or recurrent disease fare poorly with overall survival rates of less than 20%. Areas covered: This review outlines the current and future approach towards the treatment of osteosarcoma. A literature search was performed utilizing PubMed. Several recent clinical trials are reviewed in detail, as is innovative research evaluating novel agents and surgical techniques which hold promise. Expert commentary: The outcome for patients with osteosarcoma has not changed in several decades. This plateau in survival rates highlights the need for a novel approach towards research. There remains a great deal of interest in utilizing the very high risk population of recurrent osteosarcoma patients to rapidly and sequentially evaluate novel agents to determine if any of these agents hold promise. Several phase II studies are ongoing or in development that offer hope based on intriguing preclinical data. Furthermore, initiatives in obtaining specimens to further explore the genetic and immunological profile behind osteosarcoma will be essential towards identifying novel pathways and targets to exploit.Keywords
This publication has 95 references indexed in Scilit:
- Surgical Guides (Patient-Specific Instruments) for Pediatric Tibial Bone Sarcoma Resection and Allograft ReconstructionSarcoma, 2013
- Compress® Knee Arthroplasty Has 80% 10-year Survivorship and Novel Forms of Bone FailureClinical Orthopaedics and Related Research, 2013
- Survival Trends and Long-Term Toxicity in Pediatric Patients with OsteosarcomaSarcoma, 2012
- Frontline treatment of localized osteosarcoma without methotrexateCancer, 2011
- Cemented Distal Femoral Endoprostheses for Musculoskeletal Tumor: Improved Survival of Modular versus Custom ImplantsClinical Orthopaedics and Related Research, 2009
- Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcomaCancer, 2009
- Osteosarcoma incidence and survival rates from 1973 to 2004Cancer, 2009
- International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly personsInternational Journal of Cancer, 2009
- Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathwaysMolecular Cancer, 2009
- A review of clinical and molecular prognostic factors in osteosarcomaZeitschrift für Krebsforschung und Klinische Onkologie, 2007